**[208] A JOURNEY TO BETTER HEALTH - TAILORING YOUR FOOD CHOICES TO YOUR GUT MICROBIOME**

**Lihi Segal1, 1 Daytwo**

* **Investment Rational**: DayTwo translates each person’s unique gut microbiome into surprising food recommendations personally tailored, for maintaining lower blood sugar levels and general health. We benefit the healthy population, as well as those with obesity, pre-diabetes, diabetics and other metabolic disorders. Our technology is based on a four-year research led by Prof. Eran Segal and Dr. Eran Elinav from the Weizmann Institute published in Cell Journal and exclusively licensed to DayTwo.
* **Business Strategy**: DayTwo offers a B2C cloud-based application that provides real-time scoring of food, for maintaining normal blood sugar levels. DayTwo will also serve as a B2B platform for companies providing value related to nutrition and microbiome, allowing them to access the personalized nutrition and microbiome profiles of their users through an API. The application will have a one-time fee plus a recurring fee.
* **Core Technology**: People respond very differently to the same food. Despite the variability, people get generalized dietary guidelines, that may induce high blood sugar responses in many cases. DayTwo’s proprietary, patent pending, machine learning algorithms integrates personal parameters and microbiome features to accurately predict the personalized post-meal glucose response to arbitrary meals.
* **Product Profile/Pipeline:** The DayTwo application initially targets the healthy and pre-diabetic individuals, and sold both directly to consumers and via partners, allowing them access to users’ Personalized Nutrition engine and Microbiome data. Partners will range from HealthPlans and Employers offering Wellness Programs to services helping with weigh loss, restaurant and grocery shopping applications, providing real time scoring of the menu, and others.
* **What's Next**? The product will be launched in 2016 in the US. DayTwo will continue to collaborate with Prof. Eran Segal and Dr. Eran Elinav from the Weizmann Institute, co-founders of DayTwo, and perform clinical trials to expand the current product to additional target populations, as well as to develop new products based on the microbiome. The company is currently raising a Series A round.